SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095760
Filing Date
2024-08-13
Accepted
2024-08-13 07:36:33
Documents
68
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrv-20240630.htm   iXBRL 10-Q 1588381
2 EX-31.1 acrv-ex31_1.htm EX-31.1 15739
3 EX-31.2 acrv-ex31_2.htm EX-31.2 15717
4 EX-32.1 acrv-ex32_1.htm EX-32.1 9811
5 EX-32.2 acrv-ex32_2.htm EX-32.2 9794
  Complete submission text file 0000950170-24-095760.txt   7508606

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20240630.xsd EX-101.SCH 1287741
71 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20240630_htm.xml XML 1179610
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 241198793
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)